demonstrated that dual indirect targeting of CD44 and MYC in CRC stem cells, using PI3K and CDK inhibitors, reduces the survival and clonogenic activity of cancer stem cells, regardless of the mutational background (59). This evidence concerns the gene CD44 and cancer.